The type of specimen used for clonoSEQ MRD testing varies based on the patient’s diagnosis.

Patients are receiving longer-term MRD monitoring with clonoSEQ.

The time from Clonality (ID) test to first Tracking MRD test can span a longer time frame for patients with myeloma.

The demographics of clonoSEQ-tested patients are consistent with overall disease demographics.

Multiple myeloma case studies

Real-world sustained minimal residual disease (MRD) negativity using NGS in multiple myeloma

When Complete Remission is Incomplete

Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients with Hematologic Malignancies: A Case-Based Monograph

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements

Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma